Cargando…

Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy

The patient was a 65-year-old man with alcoholic liver cirrhosis who had been admitted to hospital 5 times for repeated and recurrent overt hepatic encephalopathy (HE) despite numerous therapies, including disaccharide, branched-chain amino acid (BCAA) formula, L-carnitine and zinc. After the additi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujiwara, Yudai, Suzuki, Kazuyuki, Yusa, Kenji, Eizuka, Makoto, Miura, Manami, Watanabe, Yuki, Takahashi, Hiroshi, Takikawa, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079929/ https://www.ncbi.nlm.nih.gov/pubmed/33790139 http://dx.doi.org/10.2169/internalmedicine.5793-20

Ejemplares similares

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy
por: Oey, Rosalie C., et al.
Publicado: (2019)

Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
por: Roggeri, Daniela Paola, et al.
Publicado: (2017)

Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
por: Torre, Aldo, et al.
Publicado: (2023)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
por: Cheng, Junxiong, et al.
Publicado: (2021)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Early identification using the referral system prolonged the time to onset for hepatic encephalopathy after diagnosing severe acute liver injury
por: Kakisaka, Keisuke, et al.
Publicado: (2020)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Usefulness of the Stroop Test in Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy
por: Hanai, Tatsunori, et al.
Publicado: (2021)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study
por: Kawaratani, Hideto, et al.
Publicado: (2022)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Effect of Selenium Deficiency on the Development of Overt Hepatic Encephalopathy in Patients with Chronic Liver Disease
por: Nakahata, Yuki, et al.
Publicado: (2023)

A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
por: Fritz, Cassandra D.L., et al.
Publicado: (2014)

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
por: Ballester, María-Pilar, et al.
Publicado: (2022)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
por: Wu, Dong, et al.
Publicado: (2013)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
por: Wang, Zhida, et al.
Publicado: (2018)

Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin
por: Seifert, Leon Louis, et al.
Publicado: (2021)

Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
por: Tan, Wei, et al.
Publicado: (2022)

Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It?
por: Faccioli, Jessica, et al.
Publicado: (2023)

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
por: Bajaj, J S, et al.
Publicado: (2015)

Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy
por: Mangas-Losada, Alba, et al.
Publicado: (2019)

Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy
por: Chautant, Fiona, et al.
Publicado: (2020)

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
por: Fu, Jian, et al.
Publicado: (2022)

Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species
por: Yukawa‐Muto, Yoshimi, et al.
Publicado: (2022)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
por: Wang, Ming-Wei, et al.
Publicado: (2023)

Endoscopic Removal of a Denture Lining Material Stuck in the Duodenum
por: Eizuka, Makoto, et al.
Publicado: (2022)

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
por: Roggeri, Daniela Paola, et al.
Publicado: (2015)

Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal
por: Pawar, Vinay B., et al.
Publicado: (2019)

Predicting overt hepatic encephalopathy after TIPS: Value of three minimal hepatic encephalopathy tests
por: Ehrenbauer, Alena F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d69jo3ono5r42gnkltvqq25663